Developing tests for early detection of aggressive prostate cancer
Michigan-VUMC Biomarker Characterization Center
This study is working on new urine tests to help find aggressive prostate cancer early, so that patients can get better risk assessments and personalized treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10891585 on NIH RePORTER |
What this research studies
This research focuses on creating and validating advanced diagnostic tests to detect aggressive prostate cancer at an early stage. The team, consisting of experts from the University of Michigan and Vanderbilt University Medical Center, aims to enhance existing tests by incorporating new biomarkers that indicate the presence of lethal cancer. Patients will benefit from improved risk assessments and personalized treatment options based on these tests, which utilize urine samples to identify specific cancer-related genetic markers. The project emphasizes collaboration between academic institutions and industry to ensure the tests are clinically applicable and effective.
Who could benefit from this research
Good fit: Ideal candidates for this research include African American men at risk for prostate cancer, particularly those with a family history or other risk factors.
Not a fit: Patients who do not have prostate cancer or are not at risk for developing prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of aggressive prostate cancer, improving treatment outcomes for patients.
How similar studies have performed: Previous research has successfully identified biomarkers for prostate cancer detection, indicating that this approach has potential for further advancements.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Chinnaiyan, Arul M — University of Michigan at Ann Arbor
- Study coordinator: Chinnaiyan, Arul M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.